A Phase 3 interventional study of IPX066 and CLE in Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 24 sites in 4 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2019-10-29.
Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 7th largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 3, and was the 8th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:
Impax Laboratories, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2010.
This study's enrollment of 110 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 77 across the 14 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Impax Laboratories, LLC, one of the names counted as Amneal Pharmaceuticals, Inc.. Under that name alone:
Impax Laboratories, LLC is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced Parkinson's disease.
This is a randomized, double-blind, double-dummy, 2 treatment, 2-period crossover study followed by an open-label extension study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Currently being treated with carbidopa/levodopa/entacapone (CLE) and on a stable regimen of conventional LD for at least 4 weeks and:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose conversion from CLE to IPX066, IPX066 (Part 1 Period 1), Open-label IPX066, CLE (Part 1 Period 2), OLE (Part 2)
Drug: IPX066 · Drug: CLE
Dose conversion from CLE to IPX066, CLE (Part 1 Period 1), Open-label IPX066, IPX066 (Part 1 Period 2), OLE (Part 2)
Drug: IPX066 · Drug: CLE
experimental product
Also known as: extended-release carbidopa-levodopa
Drug pages: Carbidopa · Levodopa · Entacapone
active comparator
Also known as: carbidopa/levodopa/entacapone
Percentage of "OFF" Time During Waking Hours
Using a Parkinson's disease diary, subjects recorded a state of "asleep", "OFF", "ON without dyskinesia," "ON with non-troublesome dyskinesia," or "ON with troublesome dyskinesia" every 30 minutes over a 24-hour day for the last 3 days of each double-blind crossover treatment period. Mean percentage of "OFF" Time During Waking Hours was calculated. "Off" Time is Time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness.
Time frame: 3 days of data immediately prior to the end of each 2 week treatment period
Total "OFF" Time During Waking Hours
Using a Parkinson's disease diary, subjects recorded a state of "asleep", "OFF", "ON without dyskinesia," "ON with non-troublesome dyskinesia," or "ON with troublesome dyskinesia" every 30 minutes over a 24-hour day for the last 3 days of each double-blind crossover treatment period. Mean Total "Off" Time During Waking Hours was calculated. "Off" Time is Time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness.
Time frame: 3 days of data immediately prior to the end of each 2 week treatment period
Total "On" With No Troublesome Dyskinesia
Using a Parkinson's disease diary, subjects recorded a state of "asleep", "OFF", "ON without dyskinesia," "ON with non-troublesome dyskinesia," or "ON with troublesome dyskinesia" every 30 minutes over a 24-hour day for the last 3 days of each double-blind crossover treatment period. Mean Total "On" with No Troublesome Dyskinesia was calculated. "On" Time is when medication is providing benefit with regard to mobility, slowness, and stiffness.
Time frame: 3 days of data immediately prior to the end of each 2 week treatment period
UPDRS Part II Plus Part III
Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) and Part III (Motor Examination). Part II consists of 14 questions, each ranges from 0 (Normal/None) - 4 (Worst) with a total score of 0 - 72. Part III consists of 27 questions, each ranges from 0 (Normal/None) - 4 (Worst) with a total score of 0 - 108. The UPDRS Part II Plus Part III scores ranged from 0 (no problems with daily living or mobility) to 180 (severe problems with daily living and mobility.
Time frame: End of each double-blind treatment period.
Subject Preference
Subjects who completed both treatments were asked to indicate a preference for Treatment Period 1 or Treatment Period 2 or no preference. Preferences for a particular treatment period were mapped to the associated treatment and reported.
Time frame: End of Study (week 11)
Date first patient enrolled: March 22, 2011 Date last patient completed: January 12, 2012
| Milestone | IPX066 Conversion | IPX066-Open-label IPX066 Washout-CLE-OLE | CLE-Open Label IPX066 Washout-IPX066-OLE |
|---|---|---|---|
| Started | 110 | 0 | 0 |
| Completed | 91 | 0 | 0 |
| Not completed | 19 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 0 |
| Withdrew: Lack of efficacy | 7 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 0 | 0 |
| Withdrew: Diary imcomplete | 1 | 0 | 0 |
| Milestone | IPX066 Conversion | IPX066-Open-label IPX066 Washout-CLE-OLE | CLE-Open Label IPX066 Washout-IPX066-OLE |
|---|---|---|---|
| Started | 0 | 48 | 43 |
| Completed | 0 | 46 | 43 |
| Not completed | 0 | 2 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Milestone | IPX066 Conversion | IPX066-Open-label IPX066 Washout-CLE-OLE | CLE-Open Label IPX066 Washout-IPX066-OLE |
|---|---|---|---|
| Started | 0 | 46 | 43 |
| Completed | 0 | 45 | 41 |
| Not completed | 0 | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Milestone | IPX066 Conversion | IPX066-Open-label IPX066 Washout-CLE-OLE | CLE-Open Label IPX066 Washout-IPX066-OLE |
|---|---|---|---|
| Started | 0 | 45 | 41 |
| Completed | 0 | 45 | 39 |
| Not completed | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Noncompliance | 0 | 0 | 1 |
| Milestone | IPX066 Conversion | IPX066-Open-label IPX066 Washout-CLE-OLE | CLE-Open Label IPX066 Washout-IPX066-OLE |
|---|---|---|---|
| Started | 0 | 39 | 35 |
| Completed | 0 | 36 | 30 |
| Not completed | 0 | 3 | 5 |
| Withdrew: Adverse event | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 4 |
Using a Parkinson's disease diary, subjects recorded a state of "asleep", "OFF", "ON without dyskinesia," "ON with non-troublesome dyskinesia," or "ON with troublesome dyskinesia" every 30 minutes over a 24-hour day for the last 3 days of each double-blind crossover treatment period. Mean percentage of "OFF" Time During Waking Hours was calculated. "Off" Time is Time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness.
| Percent | IPX066 | CLE (Active Comparator) |
|---|---|---|
| Percentage of "OFF" Time During Waking Hours | 23.98 ± 16.242 | 32.48 ± 21.917 |
Using a Parkinson's disease diary, subjects recorded a state of "asleep", "OFF", "ON without dyskinesia," "ON with non-troublesome dyskinesia," or "ON with troublesome dyskinesia" every 30 minutes over a 24-hour day for the last 3 days of each double-blind crossover treatment period. Mean Total "Off" Time During Waking Hours was calculated. "Off" Time is Time when medication has worn off and is no longer providing benefit with regard to mobility, slowness, and stiffness.
| hours | IPX066 | CLE (Active Comparator) |
|---|---|---|
| Total "OFF" Time During Waking Hours | 3.82 ± 2.558 | 5.22 ± 3.672 |
Using a Parkinson's disease diary, subjects recorded a state of "asleep", "OFF", "ON without dyskinesia," "ON with non-troublesome dyskinesia," or "ON with troublesome dyskinesia" every 30 minutes over a 24-hour day for the last 3 days of each double-blind crossover treatment period. Mean Total "On" with No Troublesome Dyskinesia was calculated. "On" Time is when medication is providing benefit with regard to mobility, slowness, and stiffness.
| hours | IPX066 | CLE (Active Comparator) |
|---|---|---|
| Total "On" With No Troublesome Dyskinesia | 11.36 ± 3.259 | 9.98 ± 3.764 |
Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) and Part III (Motor Examination). Part II consists of 14 questions, each ranges from 0 (Normal/None) - 4 (Worst) with a total score of 0 - 72. Part III consists of 27 questions, each ranges from 0 (Normal/None) - 4 (Worst) with a total score of 0 - 108. The UPDRS Part II Plus Part III scores ranged from 0 (no problems with daily living or mobility) to 180 (severe problems with daily living and mobility.
| Scores on a scale | IPX066 | CLE (Active Comparator) |
|---|---|---|
| UPDRS Part II Plus Part III | 29.3 ± 15.02 | 31.7 ± 14.89 |
Subjects who completed both treatments were asked to indicate a preference for Treatment Period 1 or Treatment Period 2 or no preference. Preferences for a particular treatment period were mapped to the associated treatment and reported.
| Participants | Number of Participants Who Preferred IPX066 | Number of Participants Who Preferred CLE | Number of Participants Who Had no Preference |
|---|---|---|---|
| Subject Preference | 44 | 23 | 17 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Conversion | — | 2/91 (2.2%) | 14/91 (15.4%) |
| IPX066 | — | 1/89 (1.1%) | 13/89 (14.6%) |
| CLE (Active Comparator) | — | 0/88 (0%) | 2/88 (2.3%) |
| Washout | — | 1/89 (1.1%) | 1/89 (1.1%) |
| Event | Dose Conversion | IPX066 | CLE (Active Comparator) | Washout |
|---|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | 0/91 | 0/89 | 0/88 | 1/89 |
| SciaticaNervous system disorders | 0/91 | 1/89 | 0/88 | 0/89 |
| Atrial FibrillationCardiac disorders | 1/91 | 0/89 | 0/88 | 0/89 |
| Gastrointestinal ToxicityGastrointestinal disorders | 1/91 | 0/89 | 0/88 | 0/89 |
| ConstipationGastrointestinal disorders | 1/91 | 0/89 | 0/88 | 0/89 |
| HypercalemiaMetabolism and nutrition disorders | 1/91 | 0/89 | 0/88 | 0/89 |
| Event | Dose Conversion | IPX066 | CLE (Active Comparator) | Washout |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 6/91 | 1/89 | 0/88 | 0/89 |
| DyskinesiaNervous system disorders | 1/91 | 4/89 | 0/88 | 1/89 |
| InsomniaPsychiatric disorders | 1/91 | 3/89 | 0/88 | 0/89 |
| Confusional StatePsychiatric disorders | 0/91 | 3/89 | 0/88 | 0/89 |
| FallInjury, poisoning and procedural complications | 2/91 | 1/89 | 2/88 | 0/89 |
| Upper Respiratory InfectionInfections and infestations | 2/91 | 0/89 | 0/88 | 0/89 |
| VomitingGastrointestinal disorders | 2/91 | 1/89 | 0/88 | 0/89 |
Participants who completed the Dose Conversion period and were randomized into the double-blind crossover portion of the study.
| Age, Categorical(Participants) | All Study Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 50 |
| >=65 years | 41 |
| Age, Continuous(years) | All Study Participants |
|---|---|
| Mean | 64.1 ± 9.34 |
| Sex: Female, Male(Participants) | All Study Participants |
|---|---|
| Female | 23 |
| Male | 68 |
| Ethnicity (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| Hispanic or Latino | 8 |
| Not Hispanic or Latino | 79 |
| Unknown or Not Reported | 4 |
| Race (NIH/OMB)(Participants) | All Study Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 89 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
| Region of Enrollment(participants) | All Study Participants |
|---|---|
| United States | 44 |
| Italy | 26 |
| Germany | 21 |
Plan to share: No
The record gives a start of May 2010, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2017, 5 years 8 months after primary completion. A results delay was requested in Sep 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.